id000029
10.3205/id000029
urn:nbn:de:0183-id0000293
Research Article
Decreased protein binding of moxifloxacin in patients with sepsis?
Dorn
Dorn
Christoph
C
Dr.
Klinische Pharmazie, Institut für Pharmazie der Universität Regensburg, Universitätsstraße 31, 93053 Regensburg, GermanyDept. of Clinical Pharmacy, Institute of Pharmacy, University of Regensburg, Germany
christoph.dorn@ur.de
author
Nowak
Nowak
Hartmuth
H
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Germany
author
Weidemann
Weidemann
Caroline
C
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Germany
author
Martini
Martini
Stefan
S
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Germany
author
Zeitlinger
Zeitlinger
Markus
M
Dept. of Clinical Pharmacology, Medical University of Vienna, Austria
author
Adamzik
Adamzik
Michael
M
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Germany
author
Kees
Kees
Frieder
F
Dept. of Pharmacology, University of Regensburg, Germany
author
German Medical Science GMS Publishing House
Düsseldorf
610
fluoroquinolone
unbound fraction
ultrafiltration
septic shock
20170203
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
2195-8831
5
GMS Infectious Diseases
GMS Infect Dis
03
Paul-Ehrlich-Gesellschaft für Chemotherapie
The mean (SD) unbound fraction of moxifloxacin in plasma from patients with severe sepsis or septic shock was determined by ultrafiltration to 85.5±3.0% (range 81.9 and 91.6%) indicating a decreased protein binding of moxifloxacin in this population compared with the value of 58–60% provided in the Summary of Product Characteristics. However, previous investigations neglected the influence of pH and temperature on the protein binding of moxifloxacin. Maintaining physiological conditions (pH 7.4, 37°C) – as in the present study – the unbound fraction of moxifloxacin in plasma from healthy volunteers was 84%. In contrast, the unbound fraction of moxifloxacin was 77% at 4°C and 66–68% in unbuffered plasma or at pH 8.5 in fair agreement with previously published data. PK/PD parameters e.g. fAUC/MIC or ratios between interstitial fluid and free plasma concentrations, which were obtained assuming a protein binding rate of moxifloxacin of 40% or more, should be revised.
IntroductionMoxifloxacin is a fluoroquinolone with excellent activity against a broad spectrum of microorganisms involved in soft tissue infections . Total tissue concentrations of moxifloxacin reach or exceed the corresponding plasma concentrations . However, concentrations determined in tissue homogenate should be interpreted with caution, most importantly because no distinction can be made between the intra- and extracellular concentrations , . Particularly, high concentrations of fluoroquinolones in tissue homogenate could be due to enrichment within the cells, whereas most bacterial infections occur in the extracellular space . Therefore, measurement of interstitial concentrations, e.g. by microdialysis, is to be preferred whenever possible . As the interstitial concentrations are basically free drug concentrations, the combination of measurement of the free plasma concentrations and the interstitial concentrations is the best way to get reliable results on the tissue concentrations of antibiotics and the tissue to plasma ratio. Previous studies have demonstrated that rapid or complete equilibration of antibiotics between plasma and tissue cannot be taken for granted for each clinical setting and patient population, particularly for those patients who suffer from substantially impaired local or systemic blood flow . Hence, in the present study the kinetics of moxifloxacin were investigated in plasma as well as in interstitial fluid of patients with sepsis after single and multiple dosing using microdialysis technique. Here we report the results from the measurement of free moxifloxacin in plasma.
MethodsPatients and study designThe plasma samples were obtained from a single-center non-controlled pharmacokinetic study in adult ICU patients with severe sepsis or septic shock . The aim of the study was to assess the plasma and tissue pharmacokinetics of moxifloxacin using microdialysis. The study was approved by the Ethics Committee of the Medical Faculty of the Ruhr-University Bochum (reference no. 4830-13). Written informed consent was obtained from either the patient or their legal representative. The patients received moxifloxacin 400 mg (Avalox 400 mg/250 mL solution for infusion, Bayer Vital GmbH, D-51368 Leverkusen, Germany) once daily as one-hour infusion. Arterial blood (LiHeparin monovette, Sarstedt Nümbrecht, Germany) and microdialysate was collected before infusion (baseline) and up to 10 hours on day 1, 3 and 5 of treatment. The blood was centrifuged and the plasma separated. All samples were stored at –80°C for up to <![CDATA[12 months</PlainText></TextGroup>, shipped to the analytical laboratory in dry ice and then stored further at –70°C for up to 2 months before analysis.</Pgraph><SubHeadline>Chemicals</SubHeadline><Pgraph>Moxifloxacin hydrochloride (MXF-HCl) and Avalox <TextGroup><PlainText>400 mg</PlainText></TextGroup>/250 mL (1 mL solution for infusion contains <TextGroup><PlainText>1.6 mg</PlainText></TextGroup>/mL moxifloxacin) was obtained from Bayer Vital GmbH, Leverkusen. The internal standard gatifloxacin was obtained from Grünenthal GmbH, Aachen, Germany. Acetonitrile and methanol (both HPLC gradient grade) and the other chemicals were purchased from VWR, Darmstadt, Germany. HPLC grade water was produced with an Arium basic water purification system (Sartorius, Göttingen, Germany). Blank plasma was obtained from healthy volunteers.</Pgraph><SubHeadline>Stock solutions, calibrators (STD), and quality control samples</SubHeadline><Pgraph>Moxifloxacin and gatifloxacin (IS) stock solutions (<TextGroup><PlainText>100 mg/L</PlainText></TextGroup>) were made in 0.01 M hydrochloric acid (HCl). Aliquots of the stock solutions were stored at –70°C and thawed before use. Residuals of thawed solutions were discarded. The standards (STD) and quality control (QC) samples were prepared by dilution in 0.1M HCl/MeOH 70:30 (v/v) and finally 1:20 (v/v) with plasma. STDs and QCs were stored at –70°C for no longer than 3 months until use. </Pgraph><SubHeadline>Sample preparation</SubHeadline><Pgraph>Total moxifloxacin was determined in all blood samples as published previously <TextLink reference="8"></TextLink> with minor modifications. In brief, 100 µL internal standard (iS) solution (gatifloxacin 1 mg/L in 0.2% Na-EDTA, pH 6–7) was mixed with <TextGroup><PlainText>100 µL</PlainText></TextGroup> plasma and 400 µL acetonitrile. The mixture was vortexed for 2–3 seconds, incubated for 15 min at 4°C and centrifuged. An aliquot (300 µL) of the supernatant was filled into the HPLC vials and diluted with 300 µL 0.01 M hydrochloric acid (in order to reduce peak broadening due to the high elution strength of the injection solution). An aliquot of 1–3 µL was injected into the HPLC system. <TextGroup><PlainText>Intra-</PlainText></TextGroup> and inter-assay imprecision as well as accuracy, based on in-process controls (2.5, 0.8 and 0.25 mg/L), were <4% and 100%, respectively. The concentrations of free moxifloxacin were determined by ultrafiltration applying a published method <TextLink reference="9"></TextLink> in part of patient samples: prior to first administration (blank value), after 1 hour (end of infusion, high concentration) and after <TextGroup><PlainText>10 hours</PlainText></TextGroup> (low concentration). In brief, 10 µL 3 M potassium phosphate buffer, pH 7.5, was pipetted into the ultrafiltration device (Nanosep Omega 10K, VWR, Darmstadt, Germany) and mixed with 300 µL plasma. Following incubation (10 min, 37°C, 100 g) in an Eppendorf 5417R centrifuge (Eppendorf, Hamburg, Germany) and centrifugation (20 min, 37°C, 1000 g), an aliquot (1–3 µL) of the ultrafiltrate (70–90 µL) was injected into the HPLC system. Unspecific adsorption of moxifloxacin to the UF device was assessed by filtration of 400 µL moxifloxacin 10, 3, 1, 0.3, 0.1, 0.03 or 0.01 mg/L in 0.1 M potassium phosphate buffer, pH 7.4 (2 min, 1000 g, ambient temperature). The recovery of moxifloxacin was constant over the whole range and amounted to 96.8±5.1% (mean±SD of 3 dilution series with 7 concentrations each). The intra-assay precision was not determined, as preliminary results revealed an intra-assay imprecision of <1%. The unbound fraction of moxifloxacin in a control pool (spiked with moxifloxacin 4 or 0.4 mg/L) from healthy volunteers analysed with each run was 82.6±1.8% (n=5) which corresponds to an imprecision of 1.9%. The accuracy cannot be specified, as the true value of the unbound fraction of the drug in plasma is not known. The potential concentration dependence of the protein binding of moxifloxacin was examined/checked analysing 6 independent dilution series in pooled plasma from healthy volunteers with moxifloxacin 10, 3, 1, 0.3, 0.1, 0.03 and 0.01 mg/L. </Pgraph><SubHeadline>Chromatography</SubHeadline><Pgraph>Chromatography was performed on a Prominence Modular HPLC equipped with a fluorimetric detector RF10AXL, set to ex/em 296/504 nm (Shimadzu, Duisburg, Germany). The autosampler was cooled to 6°C, the column temperature was 40°C. The separation system included a guard column 4x3 mm filled with Nucleoshell RP 18, 2.7 µ silicagel and an analytical column Nucleodur C18 HTec 3 µ, 125x4 mm. The mobile phase consisted of <TextGroup><PlainText>800 ml</PlainText></TextGroup> water, 200 ml acetonitrile, 1600 mg tetrabutylammonium hydrogen sulfate, 800 µl phosphoric acid 85%, pH 3.0 with sodium hydroxide. Gatifloxacin (iS) eluted after 1.8 min and moxifloxacin after 2.4 min at a flow rate of 0.8 mL/min.</Pgraph><SubHeadline>Statistical analysis</SubHeadline><Pgraph>GraphPad Prism 6.0 for MacOSX (GraphPad Software, <TextGroup><PlainText>La Jolla</PlainText></TextGroup>, CA, USA) was used for calculating nonparametric or parametric descriptive statistics. Least square analysis of dilution series was performed using the weighting factor 1/y<Superscript>2</Superscript>. Data are presented as mean (±SD), median or (interquartile) range, as appropriate. Unbound fraction (<Mark2>f</Mark2>u) in pool plasma has been calculated as measured free concentration/nominal concentration, whereas <Mark2>f</Mark2>u in patient plasma has been calculated as measured free concentration/measured total concentration in the respective plasma sample. </Pgraph></TextBlock>
<TextBlock linked="yes" name="Results">
<MainHeadline>Results</MainHeadline><Pgraph>Unspecific binding of moxifloxacin onto the ultrafiltration membrane was negligible. Therefore, the results are not corrected for unspecific binding. The protein binding of moxifloxacin in pool plasma from the healthy volunteers was independent of the concentration. The dilution series (range 10.0–0.01 mg/L) was perfectly linear (r=1.000, y=0.843*x+0.000) revealing a mean unbound fraction of 84.3%. Therefore, we considered it sufficient to measure the free plasma concentrations of moxifloxacin only in a part of the patient samples (after 1 hour and after 10 hours). Additionally, as the total plasma concentrations of moxifloxacin were similar on day 1, 3 and 5 (peak concentrations averaged over all 10 patients were 3.16±0.27 mg/L at the end of infusion (1 hour) and 1.01±0.13 mg/L after 10 hours, respectively), the concentrations of each patient were averaged to calculate the individual unbound fraction. Thus, the mean unbound fraction of moxifloxacin in plasma of the 10 patients was 85.5±3.0% (range 81.9 and 91.6%) with a mean intrai<TextGroup><PlainText>nd</PlainText></TextGroup>ividual coefficient of variation of 2.4% (Figure 1 <ImgLink imgNo="1" imgType="figure"/>).</Pgraph><Pgraph>The unbound fraction was higher than the value of 58–60% provided by the manufacturer (Fachinformation Avalox 400 mg/250 ml Infusionslösung, date 06/2015, Bayer Vital, Leverkusen, Germany). In order to explain the discrepancy, the influence of experimental variables such as temperature and pH were investigated. Temperature had a slight influence on the unbound fraction of moxifloxacin which increased from 77% at 5°C to 85–86% at 25–37°C (Figure 2 <ImgLink imgNo="2" imgType="figure"/>).</Pgraph><Pgraph>To examine the influence of pH, plasma was spiked with moxifloxacin 3 or 0.3 mg/L and buffered with potassium phosphate, HEPES or TRIS to pH ranging from 7.0 to 8.5 as described recently <TextLink reference="10"></TextLink>. For comparison, unbuffered plasma was analysed as well. The unbound fraction was 79–84% at pH 7.0 to 7.4 and decreased to 66–68% at pH 8.5 or in unbuffered plasma (Figure 3 <ImgLink imgNo="3" imgType="figure"/>). </Pgraph></TextBlock>
<TextBlock linked="yes" name="Discussion">
<MainHeadline>Discussion</MainHeadline><Pgraph>Antiinfective drugs are commonly evaluated on the basis of pharmacokinetic/pharmacodynamic (PK/PD) indices, all of which are based on a comparison of its plasma concentrations and the minimal inhibitory concentration (MIC) against the pathogen. However, plasma protein binding affects the antimicrobial activity of fluoroquinolones <TextLink reference="11"></TextLink>. Consequently, all PK/PD indices should refer to the unbound (non-protein bound) fraction of a drug <TextLink reference="12"></TextLink>. In addition, the concentrations in the interstitial fluid are considered to equal the free plasma concentrations. Therefore, it was reasonable to determine not only the concentrations of moxifloxacin in the intersitial fluid in the present microdialysis study, but also the free plasma concentrations in a subset of plasma samples.</Pgraph><Pgraph>The plasma protein binding of moxifloxacin in man is about 40% according to the SPC and previously published data <TextLink reference="11"></TextLink>, <TextLink reference="13"></TextLink>, <TextLink reference="14"></TextLink>. Our results indicate a lower plasma protein binding of moxifloxacin in patients with sepsis. Hypoalbuminaemia is often observed in critically ill patients <TextLink reference="15"></TextLink>, <TextLink reference="16"></TextLink> and is readily used to explain reduced protein binding in such patients <TextLink reference="16"></TextLink>. However, the protein binding of moxifloxacin in plasma of healthy volunteers was also about 15% only. On the other hand, the mean unbound fraction of moxifloxacin was lower in plasma buffered to pH 8.5 or in plain plasma, where the pH raises above 8 or reaches even 9 after preparation and storage <TextLink reference="17"></TextLink>. This behaviour is typical for basic drugs which become more lipophilic at alkaline pH <TextLink reference="17"></TextLink>. Accordingly, no pH dependency has been observed with neutral antimicrobials such as linezolid or fluconazole <TextLink reference="10"></TextLink>, whereas the protein binding of tigecycline, a tetracycline with an excess of amino functions, increases dramatically at pH>8 <TextLink reference="18"></TextLink>. Fluoroquinolones are zwitterions and most lipophilic at the isoelectric point, which is 8.0 for moxifloxacin. This unusual high isoelectric point of moxifloxacin may explain the higher protein binding of moxifloxacin at elevated pH. Accordingly, also the penetration into the alkalotic human prostate secret was highest for moxifloxacin compared with other fluoroquinolones <TextLink reference="19"></TextLink>. To sum up, strict pH and temperature control is necessary when studying protein binding <TextLink reference="17"></TextLink>. There are numerous publications reporting and discussing data that have been produced without sufficient control of these parameters <TextLink reference="17"></TextLink> including moxifloxacin <TextLink reference="11"></TextLink>, <TextLink reference="20"></TextLink>. There is one publication reporting a protein binding of 54±14% in human serum despite adjusting the pH to 7.0–7.5 and pre-incubation of serum at 37°C <TextLink reference="14"></TextLink>. However, hydrochloric acid has been used for pH adjustment, which has no buffer properties at physiological pH. Moreover, the high coefficient of variation (26%) indicates that the method used was imprecise and presumably not reliable. To sum up, it should be appropriate to assume an unbound fraction of moxifloxacin of 85% in man concerning PK/PD calculations <TextLink reference="12"></TextLink>.</Pgraph><Pgraph>We use phosphate buffer in our standard procedure <TextLink reference="9"></TextLink> in analogy to the buffer system used in equilibrium dialysis <TextLink reference="21"></TextLink>, which still is considered as “gold standard” for the determination of free drug concentrations <TextLink reference="22"></TextLink>. However, experiments with tigecycline revealed a significant higher unbound fraction, when the plasma was buffered with phosphate compared with HEPES <TextLink reference="18"></TextLink>. We assigned this observation to competition for calcium between phosphate and tigecycline. It is well known that besides tetracyclines also fluoroquinolones form chelate complexes with multivalent metal ions <TextLink reference="23"></TextLink>, <TextLink reference="24"></TextLink>. As a surprising consequence of the complex formation between tetracyclines or fluoroquinolones and calcium, lower plasma concentrations of tigecycline and ciprofloxacin were measured when blood was collected in EDTA-coated tubes instead of heparin-coated tubes. Obviously, EDTA binds plasma calcium. As a consequence, non-chelated tigecycline or ciprofloxacine diffuse into the blood cells thus lowering their plasma concentrations <TextLink reference="25"></TextLink>. Moreover, as calcium binds to albumin in a pH dependent manner <TextLink reference="26"></TextLink>, interference of phosphate buffer with the protein binding of drugs such as tetracyclines or fluoroquinolones is conceivable. Concerning moxifloxacin, the difference of the unbound fraction in phosphate or HEPES buffered plasma was statistically significant but small (84 vs 79%) and clinically irrelevant. In addition, one has to take into account that the pH cannot be exactly maintained at 7.4 either with phosphate or with HEPES. There is a small drift (ca. 0.3 pH units) upwards during ultrafiltration for 20 min at 37°C with phosphate <TextLink reference="9"></TextLink> due to evaporation of carbon dioxide. Furthermore, HEPES shows a negative pH drift with temperature in contrast to phosphate <TextLink reference="27"></TextLink>. Therefore, the statistically significant difference may partly be explained by differences in the actual pH during ultrafiltration in phosphate and HEPES buffered plasma, respectively.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Conclusion">
<MainHeadline>Conclusion</MainHeadline><Pgraph>The clinical relevance of the apparently higher unbound fraction of moxifloxacin as claimed in our study (85% compared with 60% as provided in the SPC) may be limited. However, as all PK/PD indices should be referenced to the unbound (non-protein bound) fraction of the drug <TextLink reference="12"></TextLink>, the conclusions from published studies using the 50–60% values would be slightly different. For example, the 90% probability of target attainment (<Mark2>f</Mark2>AUC/MIC=100 for Gram-negative pathogens) in patients with diabetic foot infections was achieved for pathogens with MIC≤0.125 <TextLink reference="4"></TextLink>. Taking an unbound fraction of 85% as basis, a slightly more favourable MIC≤0.18 would result. Moreover, based on microdialysis experiments, the mean ratio of AUC<Subscript>tissue</Subscript>/<Mark2>f</Mark2>AUC<Subscript>plasma</Subscript> in patients or healthy subjects was calculated between 0.7 and 1.2 <TextLink reference="6"></TextLink>, <TextLink reference="28"></TextLink>, <TextLink reference="29"></TextLink> which would change to 0.45 and 0.75.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Notes">
<MainHeadline>Notes</MainHeadline><SubHeadline>Acknowledgement</SubHeadline><Pgraph>The study was supported by an unrestricted grant from Paul-Ehrlich-Gesellschaft für Chemotherapie.</Pgraph><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock>
<References linked="yes">
<Reference refNo="1">
<RefAuthor>Raghavan M</RefAuthor>
<RefAuthor>Linden PK</RefAuthor>
<RefTitle>Newer treatment options for skin and soft tissue infections</RefTitle>
<RefYear>2004</RefYear>
<RefJournal>Drugs</RefJournal>
<RefPage>1621-42</RefPage>
<RefTotal>Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs. 2004;64(15):1621-42. DOI: 10.2165/00003495-200464150-00002</RefTotal>
<RefLink>http://dx.doi.org/10.2165/00003495-200464150-00002</RefLink>
</Reference>
<Reference refNo="2">
<RefAuthor>Justinger C</RefAuthor>
<RefAuthor>Schilling MK</RefAuthor>
<RefAuthor>Kees MG</RefAuthor>
<RefAuthor>Kauffels A</RefAuthor>
<RefAuthor>Hirschmann K</RefAuthor>
<RefAuthor>Kopp B</RefAuthor>
<RefAuthor>Kees F</RefAuthor>
<RefAuthor>Kollmar O</RefAuthor>
<RefTitle>Penetration of moxifloxacin into liver tissue</RefTitle>
<RefYear>2012</RefYear>
<RefJournal>Int J Antimicrob Agents</RefJournal>
<RefPage>505-9</RefPage>
<RefTotal>Justinger C, Schilling MK, Kees MG, Kauffels A, Hirschmann K, Kopp B, Kees F, Kollmar O. Penetration of moxifloxacin into liver tissue. Int J Antimicrob Agents. 2012 Jun;39(6):505-9. DOI: 10.1016/j.ijantimicag.2012.01.022</RefTotal>
<RefLink>http://dx.doi.org/10.1016/j.ijantimicag.2012.01.022</RefLink>
</Reference>
<Reference refNo="3">
<RefAuthor>Mouton JW</RefAuthor>
<RefAuthor>Theuretzbacher U</RefAuthor>
<RefAuthor>Craig WA</RefAuthor>
<RefAuthor>Tulkens PM</RefAuthor>
<RefAuthor>Derendorf H</RefAuthor>
<RefAuthor>Cars O</RefAuthor>
<RefTitle>Tissue concentrations: do we ever learn?</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>J Antimicrob Chemother</RefJournal>
<RefPage>235-7</RefPage>
<RefTotal>Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008 Feb;61(2):235-7. DOI: 10.1093/jac/dkm476</RefTotal>
<RefLink>http://dx.doi.org/10.1093/jac/dkm476</RefLink>
</Reference>
<Reference refNo="4">
<RefAuthor>Wicha SG</RefAuthor>
<RefAuthor>Haak T</RefAuthor>
<RefAuthor>Zink K</RefAuthor>
<RefAuthor>Kees F</RefAuthor>
<RefAuthor>Kloft C</RefAuthor>
<RefAuthor>Kees MG</RefAuthor>
<RefTitle>Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections</RefTitle>
<RefYear>2015</RefYear>
<RefJournal>J Clin Pharmacol</RefJournal>
<RefPage>639-46</RefPage>
<RefTotal>Wicha SG, Haak T, Zink K, Kees F, Kloft C, Kees MG. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. J Clin Pharmacol. 2015 Jun;55(6):639-46. DOI: 10.1002/jcph.464</RefTotal>
<RefLink>http://dx.doi.org/10.1002/jcph.464</RefLink>
</Reference>
<Reference refNo="5">
<RefAuthor>Azeredo FJ</RefAuthor>
<RefAuthor>Dalla Costa T</RefAuthor>
<RefAuthor>Derendorf H</RefAuthor>
<RefTitle>Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions</RefTitle>
<RefYear>2014</RefYear>
<RefJournal>Clin Pharmacokinet</RefJournal>
<RefPage>205-12</RefPage>
<RefTotal>Azeredo FJ, Dalla Costa T, Derendorf H. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet. 2014 Mar;53(3):205-12. DOI: 10.1007/s40262-014-0131-8</RefTotal>
<RefLink>http://dx.doi.org/10.1007/s40262-014-0131-8</RefLink>
</Reference>
<Reference refNo="6">
<RefAuthor>Joukhadar C</RefAuthor>
<RefAuthor>Stass H</RefAuthor>
<RefAuthor>Müller-Zellenberg U</RefAuthor>
<RefAuthor>Lackner E</RefAuthor>
<RefAuthor>Kovar F</RefAuthor>
<RefAuthor>Minar E</RefAuthor>
<RefAuthor>Müller M</RefAuthor>
<RefTitle>Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans</RefTitle>
<RefYear>2003</RefYear>
<RefJournal>Antimicrob Agents Chemother</RefJournal>
<RefPage>3099-103</RefPage>
<RefTotal>Joukhadar C, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, Müller M. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother. 2003 Oct;47(10):3099-103. DOI: 10.1128/AAC.47.10.3099-3103.2003</RefTotal>
<RefLink>http://dx.doi.org/10.1128/AAC.47.10.3099-3103.2003</RefLink>
</Reference>
<Reference refNo="7">
<RefAuthor>Bone RC</RefAuthor>
<RefAuthor>Balk RA</RefAuthor>
<RefAuthor>Cerra FB</RefAuthor>
<RefAuthor>Dellinger RP</RefAuthor>
<RefAuthor>Fein AM</RefAuthor>
<RefAuthor>Knaus WA</RefAuthor>
<RefAuthor>Schein RM</RefAuthor>
<RefAuthor>Sibbald WJ</RefAuthor>
<RefTitle>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</RefTitle>
<RefYear>1992</RefYear>
<RefJournal>Chest</RefJournal>
<RefPage>1644-55</RefPage>
<RefTotal>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. DOI: 10.1378/chest.101.6.1644</RefTotal>
<RefLink>http://dx.doi.org/10.1378/chest.101.6.1644</RefLink>
</Reference>
<Reference refNo="8">
<RefAuthor>Kees MG</RefAuthor>
<RefAuthor>Weber S</RefAuthor>
<RefAuthor>Kees F</RefAuthor>
<RefAuthor>Horbach T</RefAuthor>
<RefTitle>Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients</RefTitle>
<RefYear>2011</RefYear>
<RefJournal>J Antimicrob Chemother</RefJournal>
<RefPage>2330-5</RefPage>
<RefTotal>Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011 Oct;66(10):2330-5. DOI: 10.1093/jac/dkr282</RefTotal>
<RefLink>http://dx.doi.org/10.1093/jac/dkr282</RefLink>
</Reference>
<Reference refNo="9">
<RefAuthor>Kratzer A</RefAuthor>
<RefAuthor>Liebchen U</RefAuthor>
<RefAuthor>Schleibinger M</RefAuthor>
<RefAuthor>Kees MG</RefAuthor>
<RefAuthor>Kees F</RefAuthor>
<RefTitle>Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions</RefTitle>
<RefYear>2014</RefYear>
<RefJournal>J Chromatogr B Analyt Technol Biomed Life Sci</RefJournal>
<RefPage>97-102</RefPage>
<RefTotal>Kratzer A, Liebchen U, Schleibinger M, Kees MG, Kees F. Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun;961:97-102. DOI: 10.1016/j.jchromb.2014.05.021</RefTotal>
<RefLink>http://dx.doi.org/10.1016/j.jchromb.2014.05.021</RefLink>
</Reference>
<Reference refNo="10">
<RefAuthor>Kratzer A</RefAuthor>
<RefAuthor>Kees F</RefAuthor>
<RefAuthor>Dorn C</RefAuthor>
<RefTitle>Unbound fraction of fluconazole and linezolid in human plasma as determined by ultrafiltration: Impact of membrane type</RefTitle>
<RefYear>2016</RefYear>
<RefJournal>J Chromatogr B Analyt Technol Biomed Life Sci</RefJournal>
<RefPage>74-8</RefPage>
<RefTotal>Kratzer A, Kees F, Dorn C. Unbound fraction of fluconazole and linezolid in human plasma as determined by ultrafiltration: Impact of membrane type. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec;1039:74-8. DOI: 10.1016/j.jchromb.2016.10.040</RefTotal>
<RefLink>http://dx.doi.org/10.1016/j.jchromb.2016.10.040</RefLink>
</Reference>
<Reference refNo="11">
<RefAuthor>Zeitlinger M</RefAuthor>
<RefAuthor>Sauermann R</RefAuthor>
<RefAuthor>Fille M</RefAuthor>
<RefAuthor>Hausdorfer J</RefAuthor>
<RefAuthor>Leitner I</RefAuthor>
<RefAuthor>Müller M</RefAuthor>
<RefTitle>Plasma protein binding of fluoroquinolones affects antimicrobial activity</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>J Antimicrob Chemother</RefJournal>
<RefPage>561-7</RefPage>
<RefTotal>Zeitlinger M, Sauermann R, Fille M, Hausdorfer J, Leitner I, Müller M. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother. 2008 Mar;61(3):561-7. DOI: 10.1093/jac/dkm524</RefTotal>
<RefLink>http://dx.doi.org/10.1093/jac/dkm524</RefLink>
</Reference>
<Reference refNo="12">
<RefAuthor>Mouton JW</RefAuthor>
<RefAuthor>Dudley MN</RefAuthor>
<RefAuthor>Cars O</RefAuthor>
<RefAuthor>Derendorf H</RefAuthor>
<RefAuthor>Drusano GL</RefAuthor>
<RefTitle>Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update</RefTitle>
<RefYear>2005</RefYear>
<RefJournal>J Antimicrob Chemother</RefJournal>
<RefPage>601-7</RefPage>
<RefTotal>Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005 May;55(5):601-7. DOI: 10.1093/jac/dki079</RefTotal>
<RefLink>http://dx.doi.org/10.1093/jac/dki079</RefLink>
</Reference>
<Reference refNo="13">
<RefAuthor>Siefert HM</RefAuthor>
<RefAuthor>Domdey-Bette A</RefAuthor>
<RefAuthor>Henninger K</RefAuthor>
<RefAuthor>Hucke F</RefAuthor>
<RefAuthor>Kohlsdorfer C</RefAuthor>
<RefAuthor>Stass HH</RefAuthor>
<RefTitle>Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species</RefTitle>
<RefYear>1999</RefYear>
<RefJournal>J Antimicrob Chemother</RefJournal>
<RefPage>69-76</RefPage>
<RefTotal>Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother. 1999 May;43 Suppl B:69-76. DOI: 10.1093/jac/43.suppl_2.69</RefTotal>
<RefLink>http://dx.doi.org/10.1093/jac/43.suppl_2.69</RefLink>
</Reference>
<Reference refNo="14">
<RefAuthor>Ostergaard C</RefAuthor>
<RefAuthor>Sørensen TK</RefAuthor>
<RefAuthor>Knudsen JD</RefAuthor>
<RefAuthor>Frimodt-Møller N</RefAuthor>
<RefTitle>Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits</RefTitle>
<RefYear>1998</RefYear>
<RefJournal>Antimicrob Agents Chemother</RefJournal>
<RefPage>1706-12</RefPage>
<RefTotal>Ostergaard C, Sørensen TK, Knudsen JD, Frimodt-Møller N. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother. 1998 Jul;42(7):1706-12.</RefTotal>
</Reference>
<Reference refNo="15">
<RefAuthor>Roberts JA</RefAuthor>
<RefAuthor>Pea F</RefAuthor>
<RefAuthor>Lipman J</RefAuthor>
<RefTitle>The clinical relevance of plasma protein binding changes</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Clin Pharmacokinet</RefJournal>
<RefPage>1-8</RefPage>
<RefTotal>Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013 Jan;52(1):1-8. DOI: 10.1007/s40262-012-0018-5</RefTotal>
<RefLink>http://dx.doi.org/10.1007/s40262-012-0018-5</RefLink>
</Reference>
<Reference refNo="16">
<RefAuthor>Ulldemolins M</RefAuthor>
<RefAuthor>Roberts JA</RefAuthor>
<RefAuthor>Rello J</RefAuthor>
<RefAuthor>Paterson DL</RefAuthor>
<RefAuthor>Lipman J</RefAuthor>
<RefTitle>The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients</RefTitle>
<RefYear>2011</RefYear>
<RefJournal>Clin Pharmacokinet</RefJournal>
<RefPage>99-110</RefPage>
<RefTotal>Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110. DOI: 10.2165/11539220-000000000-00000</RefTotal>
<RefLink>http://dx.doi.org/10.2165/11539220-000000000-00000</RefLink>
</Reference>
<Reference refNo="17">
<RefAuthor>Nilsson LB</RefAuthor>
<RefTitle>The bioanalytical challenge of determining unbound concentration and protein binding for drugs</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Bioanalysis</RefJournal>
<RefPage>3033-50</RefPage>
<RefTotal>Nilsson LB. The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis. 2013 Dec;5(24):3033-50. DOI: 10.4155/bio.13.274</RefTotal>
<RefLink>http://dx.doi.org/10.4155/bio.13.274</RefLink>
</Reference>
<Reference refNo="18">
<RefAuthor>Kratzer A</RefAuthor>
<RefAuthor>Murschhauser A</RefAuthor>
<RefAuthor>Schleibinger M</RefAuthor>
<RefAuthor>Liebchen U</RefAuthor>
<RefAuthor>Kees M</RefAuthor>
<RefAuthor>Rothe U</RefAuthor>
<RefAuthor>Kees F</RefAuthor>
<RefTitle>In vitro investigations on the atypical protein binding behaviour of tigecycline using ultrafiltration. Abstract P1137</RefTitle>
<RefYear></RefYear>
<RefBookTitle>25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2015 Apr 25-28; Copenhagen, Denmark</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Kratzer A, Murschhauser A, Schleibinger M, Liebchen U, Kees M, Rothe U, Kees F. In vitro investigations on the atypical protein binding behaviour of tigecycline using ultrafiltration. Abstract P1137. In: 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2015 Apr 25-28; Copenhagen, Denmark.</RefTotal>
</Reference>
<Reference refNo="19">
<RefAuthor>Perletti G</RefAuthor>
<RefAuthor>Wagenlehner FM</RefAuthor>
<RefAuthor>Naber KG</RefAuthor>
<RefAuthor>Magri V</RefAuthor>
<RefTitle>Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue</RefTitle>
<RefYear>2009</RefYear>
<RefJournal>Int J Antimicrob Agents</RefJournal>
<RefPage>206-10</RefPage>
<RefTotal>Perletti G, Wagenlehner FM, Naber KG, Magri V. Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. Int J Antimicrob Agents. 2009 Mar;33(3):206-10. DOI: 10.1016/j.ijantimicag.2008.09.009</RefTotal>
<RefLink>http://dx.doi.org/10.1016/j.ijantimicag.2008.09.009</RefLink>
</Reference>
<Reference refNo="20">
<RefAuthor>Pranger AD</RefAuthor>
<RefAuthor>Alffenaar JW</RefAuthor>
<RefAuthor>Wessels AM</RefAuthor>
<RefAuthor>Greijdanus B</RefAuthor>
<RefAuthor>Uges DR</RefAuthor>
<RefTitle>Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography- tandem mass spectrometry method</RefTitle>
<RefYear>2010</RefYear>
<RefJournal>J Anal Toxicol</RefJournal>
<RefPage>135-41</RefPage>
<RefTotal>Pranger AD, Alffenaar JW, Wessels AM, Greijdanus B, Uges DR. Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography- tandem mass spectrometry method. J Anal Toxicol. 2010 Apr;34(3):135-41. DOI: 10.1093/jat/34.3.135</RefTotal>
<RefLink>http://dx.doi.org/10.1093/jat/34.3.135</RefLink>
</Reference>
<Reference refNo="21">
<RefAuthor>Curran RE</RefAuthor>
<RefAuthor>Claxton CR</RefAuthor>
<RefAuthor>Hutchison L</RefAuthor>
<RefAuthor>Harradine PJ</RefAuthor>
<RefAuthor>Martin IJ</RefAuthor>
<RefAuthor>Littlewood P</RefAuthor>
<RefTitle>Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding</RefTitle>
<RefYear>2011</RefYear>
<RefJournal>Drug Metab Dispos</RefJournal>
<RefPage>551-7</RefPage>
<RefTotal>Curran RE, Claxton CR, Hutchison L, Harradine PJ, Martin IJ, Littlewood P. Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding. Drug Metab Dispos. 2011 Mar;39(3):551-7. DOI: 10.1124/dmd.110.036988</RefTotal>
<RefLink>http://dx.doi.org/10.1124/dmd.110.036988</RefLink>
</Reference>
<Reference refNo="22">
<RefAuthor>Zhang F</RefAuthor>
<RefAuthor>Xue J</RefAuthor>
<RefAuthor>Shao J</RefAuthor>
<RefAuthor>Jia L</RefAuthor>
<RefTitle>Compilation of 222 drugs' plasma protein binding data and guidance for study designs</RefTitle>
<RefYear>2012</RefYear>
<RefJournal>Drug Discov Today</RefJournal>
<RefPage>475-85</RefPage>
<RefTotal>Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov Today. 2012 May;17(9-10):475-85. DOI: 10.1016/j.drudis.2011.12.018</RefTotal>
<RefLink>http://dx.doi.org/10.1016/j.drudis.2011.12.018</RefLink>
</Reference>
<Reference refNo="23">
<RefAuthor>Polk RE</RefAuthor>
<RefTitle>Drug-drug interactions with ciprofloxacin and other fluoroquinolones</RefTitle>
<RefYear>1989</RefYear>
<RefJournal>Am J Med</RefJournal>
<RefPage>76S-81S</RefPage>
<RefTotal>Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med. 1989 Nov 30;87(5A):76S-81S. DOI: 10.1016/0002-9343(89)90028-4</RefTotal>
<RefLink>http://dx.doi.org/10.1016/0002-9343(89)90028-4</RefLink>
</Reference>
<Reference refNo="24">
<RefAuthor>Seedher N</RefAuthor>
<RefAuthor>Agarwal P</RefAuthor>
<RefTitle>Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics</RefTitle>
<RefYear>2010</RefYear>
<RefJournal>Drug Metabol Drug Interact</RefJournal>
<RefPage>17-24</RefPage>
<RefTotal>Seedher N, Agarwal P. Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics. Drug Metabol Drug Interact. 2010;25(1-4):17-24. DOI: 10.1515/DMDI.2010.003</RefTotal>
<RefLink>http://dx.doi.org/10.1515/DMDI.2010.003</RefLink>
</Reference>
<Reference refNo="25">
<RefAuthor>Chen Q</RefAuthor>
<RefAuthor>Tung EC</RefAuthor>
<RefAuthor>Ciccotto SL</RefAuthor>
<RefAuthor>Strauss JR</RefAuthor>
<RefAuthor>Ortiga R</RefAuthor>
<RefAuthor>Ramsay KA</RefAuthor>
<RefAuthor>Tang W</RefAuthor>
<RefTitle>Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>Xenobiotica</RefJournal>
<RefPage>76-86</RefPage>
<RefTotal>Chen Q, Tung EC, Ciccotto SL, Strauss JR, Ortiga R, Ramsay KA, Tang W. Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin. Xenobiotica. 2008 Jan;38(1):76-86. DOI: 10.1080/00498250701678955</RefTotal>
<RefLink>http://dx.doi.org/10.1080/00498250701678955</RefLink>
</Reference>
<Reference refNo="26">
<RefAuthor>Pedersen KO</RefAuthor>
<RefTitle>Protein-bound calcium in human serum. Quantitative examination of binding and its variables by a molecular binding model and clinical chemical implications for measurement of ionized calcium</RefTitle>
<RefYear>1972</RefYear>
<RefJournal>Scand J Clin Lab Invest</RefJournal>
<RefPage>321-9</RefPage>
<RefTotal>Pedersen KO. Protein-bound calcium in human serum. Quantitative examination of binding and its variables by a molecular binding model and clinical chemical implications for measurement of ionized calcium. Scand J Clin Lab Invest. 1972 Nov;30(3):321-9. DOI: 10.3109/00365517209084297</RefTotal>
<RefLink>http://dx.doi.org/10.3109/00365517209084297</RefLink>
</Reference>
<Reference refNo="27">
<RefAuthor>Good NE</RefAuthor>
<RefAuthor>Winget GD</RefAuthor>
<RefAuthor>Winter W</RefAuthor>
<RefAuthor>Connolly TN</RefAuthor>
<RefAuthor>Izawa S</RefAuthor>
<RefAuthor>Singh RM</RefAuthor>
<RefTitle>Hydrogen ion buffers for biological research</RefTitle>
<RefYear>1966</RefYear>
<RefJournal>Biochemistry</RefJournal>
<RefPage>467-77</RefPage>
<RefTotal>Good NE, Winget GD, Winter W, Connolly TN, Izawa S, Singh RM. Hydrogen ion buffers for biological research. Biochemistry. 1966 Feb;5(2):467-77. DOI: 10.1021/bi00866a011</RefTotal>
<RefLink>http://dx.doi.org/10.1021/bi00866a011</RefLink>
</Reference>
<Reference refNo="28">
<RefAuthor>Müller M</RefAuthor>
<RefAuthor>Stass H</RefAuthor>
<RefAuthor>Brunner M</RefAuthor>
<RefAuthor>Möller JG</RefAuthor>
<RefAuthor>Lackner E</RefAuthor>
<RefAuthor>Eichler HG</RefAuthor>
<RefTitle>Penetration of moxifloxacin into peripheral compartments in humans</RefTitle>
<RefYear>1999</RefYear>
<RefJournal>Antimicrob Agents Chemother</RefJournal>
<RefPage>2345-9</RefPage>
<RefTotal>Müller M, Stass H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother. 1999 Oct;43(10):2345-9.</RefTotal>
</Reference>
<Reference refNo="29">
<RefAuthor>Burkhardt O</RefAuthor>
<RefAuthor>Derendorf H</RefAuthor>
<RefAuthor>Jäger D</RefAuthor>
<RefAuthor>Kumar V</RefAuthor>
<RefAuthor>Madabushi R</RefAuthor>
<RefAuthor>Röhl K</RefAuthor>
<RefAuthor>Barth J</RefAuthor>
<RefTitle>Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis</RefTitle>
<RefYear>2006</RefYear>
<RefJournal>Scand J Infect Dis</RefJournal>
<RefPage>904-8</RefPage>
<RefTotal>Burkhardt O, Derendorf H, Jäger D, Kumar V, Madabushi R, Röhl K, Barth J. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. Scand J Infect Dis. 2006;38(10):904-8. DOI: 10.1080/00365540600664076</RefTotal>
<RefLink>http://dx.doi.org/10.1080/00365540600664076</RefLink>
</Reference>
</References>
<Media>
<Tables>
<NoOfTables>0</NoOfTables>
</Tables>
<Figures>
<Figure format="png" height="286" width="236">
<MediaNo>1</MediaNo>
<MediaID>1</MediaID>
<Caption><Pgraph><Mark1>Figure 1: Unbound fraction (</Mark1><Mark1><Mark2>f</Mark2></Mark1><Mark1>u) of moxifloxacin in plasma of ICU patients with sepsis treated with moxifloxacin 400 mg i.v. once daily </Mark1><LineBreak></LineBreak>Median, IQR, circles = mean values of 6 samples per patient, dotted line = <Mark2>f</Mark2>u in pool plasma from healthy volunteers</Pgraph></Caption>
</Figure>
<Figure format="png" height="286" width="292">
<MediaNo>2</MediaNo>
<MediaID>2</MediaID>
<Caption><Pgraph><Mark1>Figure 2: Influence of temperature on the protein binding of moxifloxacin in human plasma, buffered with potassium phosphate to 7.4, as determined by ultrafiltration. Mean±SD of 4 independent experiments with moxifloxacin 3 or 0.3 mg/L (n=8)</Mark1></Pgraph></Caption>
</Figure>
<Figure format="png" height="283" width="307">
<MediaNo>3</MediaNo>
<MediaID>3</MediaID>
<Caption><Pgraph><Mark1>Figure 3: Influence of pH on the protein binding of moxifloxacin in human plasma (at 37°C) as determined by ultrafiltration. Mean±SD of 4 independent experiments with moxifloxacin 3 or 0.3 mg/L (total n=8) </Mark1><LineBreak></LineBreak>Abbr.: P phosphate, H HEPES, T TRIS, Pl plasma unbuffered</Pgraph></Caption>
</Figure>
<NoOfPictures>3</NoOfPictures>
</Figures>
<InlineFigures>
<NoOfPictures>0</NoOfPictures>
</InlineFigures>
<Attachments>
<NoOfAttachments>0</NoOfAttachments>
</Attachments>
</Media>
</OrigData>
</GmsArticle>]]></plaintext></textgroup></pgraph></textblock></origdata></gmsarticle>